BioPorto signs global distribution agreement with Roche for NGAL test

BioPorto entered into a global distribution agreement with Roche to deliver an NGAL test for use on Roche's cobas c 501/c 502 analysers. Roche will have worldwide exclusive distribution rights.

“I am very happy to enter into a collaboration with Roche, who as a dominant player in the diagnostic space will ensure a broad global distribution of our NGAL test.”globenewswire.com

• 1 source
• globenewswire.comBioPorto and Roche Diagnostics sign a distributionBioPorto A/SFeb 9, 2018

Summarized from public sources; check the original articles before acting on it.